

# **HHS Public Access**

Author manuscript

Biochemistry. Author manuscript; available in PMC 2018 August 01.

Published in final edited form as:

Biochemistry. 2017 August 01; 56(30): 3885–3888. doi:10.1021/acs.biochem.7b00461.

# Molecular simulations reveal an unresolved conformation of the Type-IA Protein Kinase A regulatory subunit and suggests its role in the cAMP regulatory mechanism


### Sophia P. Hirakis, Robert D. Malmstrom, and Rommie E. Amaro\*

Department of Chemistry and Biochemistry and National Biomedical Computational Resource, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0304

#### Abstract

We identify a previously unresolved, unrecognized, and highly stable conformation of the Protein Kinase A (PKA) regulatory subunit RIa. This conformation, which we refer to as the "Flipback" structure, bridges conflicting characteristics in the crystallographic structures and solution experiments of the PKA RIa heterotetramer. Our simulations reveal a hinge residue in the B/C helix that is conserved through all isoforms of RI. Brownian dynamics simulations suggest that the Flipback conformation plays a role in cAMP association to the A domain of R subunit.

## **Graphical Abstract**



#### **Keywords**

Molecular Dynamics; Brownian Dynamics; Protein Kinase A; PKA; cAMP

Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0304

ASSOCIATED CONTENT

Detailed experimental methods; Figure S1, MD of the Flipback structure. Figures S2, S3 and Table S2 Encounter complex; Figure S4, Electrostatic profiles of Holo and Flipback. This material is available free of charge via the Internet at http://pubs.acs.org."

#### **Author Contributions**

S.P.H. wrote the manuscript, analyzed MD, and performed and designed BD experiments. R.D.M. performed and designed MD experiments. R.E.A. directed the research. This manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

#### Notes

REA is a co-founder of, has equity interest in, and serves on the Scientific Advisory Board of Actavalon, Inc.

<sup>\*</sup>Corresponding Authors: Rommie E. Amaro, ramaro@ucsd.edu. Present Address

Protein Kinase A (PKA) is a ubiquitous eukaryotic kinase that modulates protein function through targeted phosphorylation. An ancient cellular second-messenger, cAMP, modulates the activity of PKA in a diverse set of biological processes; from synaptic plasticity  $^{\rm I}$  to cardiac signaling  $^{\rm 2}$ . Inactive PKA exists as a heterotetramer (R2C2), where two catalytic (C) subunits are maintained in the inactive state by binding to the regulatory (R) subunit homodimer. In response to extracellular signals like adrenaline adenylyl cyclase activity leads to an increase in cAMP. When four molecules of cAMP bind to the cyclic-nucleotide binding domains (CBD) of R dimer, a global conformational change in R occurs, releasing two active C subunits, free to phosphorylate protein targets. This activation cycle is the generalized mechanism for all non-redundant forms of R (RIa, RIβ, RIIa, RIIβ) and C (Ca, Cβ, Cγ). PKA subtypes are expressed in every cell and encoded by separate genes, differing in structure, activity, and cellular localization. Thus, elucidating the structural organization of PKA complexes and their relationship to activation by cAMP is important for the development of novel therapeutics and the understanding of PKA's fundamental biochemistry.

Structural biologists have elucidated PKA isoforms in various stages of the activation cycle. Although the heterotetrameric ( $R_2C_2$ ) structure of the Type-IA Protein Kinase,  $RI_\alpha$ , was never fully resolved, it has been the subject of several studies and models. Su *et al.* crystallized  $RI_\alpha$ , in complex with two molecules of cAMP.<sup>7</sup> This structure of the PKA R subunit at the end of the activation cycle, known to many as the "Bound" conformation or "B conformation" ( $R^{Bound}$ ), reveals the amino acid residues important for coordinating cAMP. Each PKA R subunit has two cyclic-nucleotide binding domains (CBD-A and CBD-B) joined by a helical moiety known as the B/C helix. The CBD is a conserved sensor of cAMP and composed of non-contiguous alpha-helices and beta barrel subdomains. At the N-terminus, a  $3_{10}$ helix-loop region (N3A motif<sup>8</sup>) is followed by a beta sandwich containing the cAMP binding site, and a terminal helical region (B and C-terminal helices). The cAMP-bound structure has served as an invaluable resource for understanding cAMP activation through molecular simulations and a premiments.

The first structure of the RC "holoenzyme" heterodimer featured the C subunit in complex with RIa CBD-A ( $R_AC$ ). <sup>10</sup> Point mutations made at key cAMP-interacting residue, Arg333<sup>R</sup> in CBD-B, led to the crystallization of the dual-domain R subunit with the C subunit "Holoenzyme" conformation or "H conformation",  $R^{Holo}$ , is different from the cAMP-bound structure, "Bound" or "B conformation",  $R^{Bound}$  (Figure 1). The Bound conformation is globular, with CBD contacts resulting from a bent B/C/C' helix. In B conformation, the B/C helix breaks at L233 and Y244 (Figure 1A), bringing N3AB in contact with CBD-A. In RCHolo structure, the R subunit wraps around C subunit (Figure 1B), and the CBDs are separated by an extended B/C helix. In the absence of C subunit, The H form is stabilized by cAMP analogs. <sup>12</sup> The cAMP bound, "B" conformation cannot physically accommodate C subunit because N3AB interacts with C in RCHolo while N3AB interacts with CBD-A in RBound (Figure 1).

Despite extensive efforts, the structure of full-length ( $R_{AB}$ ), wild-type Type-IA ( $R_{I\alpha}$ ) PKA heterotetramer remains elusive. Structural models of the tetramer are available, <sup>13</sup> but are not fully consistent with structure and dynamics of PKA in solution. Specifically, the

heterodimeric mutant R333K crystal structure has a larger R/C interface than described by hydrogen/deuterium exchange mass spectrometry (HDXMS) (Figure 1B). 14–16

Here, we use molecular simulation techniques to make sense of discordant experimental findings from X-ray crystallography, scattering and HDXMS experiments. We present a novel conformation of the regulatory subunit that resolves these disparities, the "Flipback" or "F conformation". Finally, we use electrostatic descriptions of the biomolecules to understand cAMP association offering a role for Flipback in the regulation mechanism of PKA RIa.

To understand the flexibility of the apo WT R subunit, we performed all-atom molecular dynamics (MD) simulations starting from H conformation in the absence of C subunit and cAMP. We simulated, WT Holo R in five 200ns replicates using the AMBER<sup>17</sup> force field in NTP ensemble at 310K. MD of WT-R<sup>Holo</sup> reveals a very flexible B/C helix as observed in other simulations<sup>18, 19</sup>. Mutagenesis of B/C helix residues recently showed pronounced effects on PKA activation.<sup>14</sup>

Our MD simulations reveal a unique, stable conformation of R subunit (Figure 1C, Figure S1), which we call the "Flipback" conformation or "F form", R<sup>Flipback</sup>. Like R<sup>Bound</sup>, R<sup>Flipback</sup> features inter-domain (CBD-A/B) interactions and a B/C helix break. However, R<sup>Flipback</sup> breaks in the opposite direction, with interactions between alternate CBDs and N3A motifs. R<sup>Bound</sup> uses contacts between N3A<sup>B</sup> and CBD-A while R<sup>Flipback</sup> uses N3A<sup>A</sup> to interact with CBD-B (Figure 1B and 1C). In R<sup>Flipback</sup>, the B/C helix breaks at Gly235<sup>R</sup> early in the trajectory (~20ns), bringing the CBDs in contact for the rest of the simulation in a stable conformation (Figure S1). Mutations limiting the flexibility of the B/C helix (G235P) result in poor C subunit binding<sup>20</sup> promoting activation. Residues 230–238 of B/C helix exhibit nearly equal Hydrogen-bond propensities in the Holoenzyme, cAMP-Bound, and cAMP-free forms, <sup>15</sup> suggesting the B/C helix is equally flexible in all structures. Gly235 is conserved amongst all forms of RI.<sup>21</sup> Thus, a helical break at this position may be important in the activation of other Type-I PKA R subunits.

When  $R^{Flipback}$  is aligned with CBD-A of  $RC^{Holo}$ , it is apparent that Flipback conformation *can* accommodate C subunit, unlike  $R^{Bound}$ . We created a PKA  $R_2C_2$  model using F conformation ( $R_2C_2^{Flipback}$ ). As Flipback and Holo are the only known conformations that can accommodate C subunit, we were curious to understand how conformational changes in R affect cAMP association. The diffusion of cAMP, a polar molecule, is likely influenced by long-range electrostatic forces which are estimated computationally by Brownian Dynamics (BD) simulation methods.  $^{22-24}$ 

Using the existing  $^{13}$  and newly constructed models of PKA heterotetramer and heterodimer ( $R_2C_2^{Holo}$ ,  $R_2C_2^{Flipback}$  and  $RC^{Holo}$ ,  $RC^{Flipback}$ ) we examine the relative rate of cAMP encounter to CBD-A and CBD-B via BD simulations to determine association rates ( $k_{association}$ ). An "encounter complex" is formed when a specified distance between a set of atoms is reached. We chose three conserved residues to define encounter complexes in CBD-A/B: Val184/300, Glu200/324, and Arg209/333 (Figure S2, Table S1). Using BrownDye,  $^{25}$ 

we compare the effect of Holo and Flipback on cAMP association tetrameric and heterodimeric in conformations.

Predicted BD rates are remarkably consistent with apparent  $k_{on}$  from experiments:<sup>26</sup> 4.52 x  $10^6$  and 1.00 x  $10^5$  (CBD-B and CBD-A, respectively). The fastest rate of cAMP encounter to PKA tetramers is to  $R_2C_2^{Holo}$  CBD-B ( $\sim 10^7$  M $^{-1}$ s $^{-1}$ ) while CBD-A association is slowest ( $\sim 10^5$  M $^{-1}$ s $^{-1}$ , see Table 1). Domain-B preference in Holo validates the standing "gate-keeper" theory of PKA RI $_{\alpha}$ , which holds that cAMP binds to CBD-B first.<sup>27</sup> Domain B preference is neutralized in  $R_2C_2^{Flipback}$ , where both CBD-A and CBD-B bind on the order of  $\sim 10^6$  M $^{-1}$ s $^{-1}$  (Table 1 and Scheme 1).

Electrostatically, the systems differ in the distribution of charge on the surfaces of PKA complexes. Flipback has a more electropositive CBD-A than Holo (Figure S4), yielding a higher association rate by cAMP. The phenomenological preference for CBD-A of Flipback is most pronounced in heterodimers, with association rates two to four orders of magnitude higher in F. This difference in association rates is due to the very different electrostatic potential surfaces of the heterodimer vs. heterotetramer forms in H and F conformations (see Figure S4). From these results, we hypothesize that the Flipback conformation is important for cAMP association to CBD-A. It is not known if RC heterodimers are important players in the activation mechanism of PKA; but if they are, we predict that the Flipback conformation plays a role in CBD-A association.

The only resolved conformation of full-length R in complex with C necessitated the R333K mutation to stabilize CBD-B.  $^{11}$  However, it has been shown that R333K mutant (RCHolo) has a different solution structure than WT. Small-angle X-ray scattering (SAXS) of full-length WT heterodimer and heterotetramer  $^{28}$  exhibit a shouldering region; one not observed in symmetric SAXS p(r) distributions of mutant RC (R333K) and  $R_{\rm A}C$ , a heterodimer lacking the B domain.  $^{29}$ 

The Flipback heterotetramer structure corroborates observations from multiple solution experiments. First, the C subunit interface of the WT full-length holoenzyme measured by HDXMS is consistent with R/C interface of the R<sub>2</sub>C<sub>2</sub>Flipback structure, where the amides of residues 212–221<sup>C</sup> and 278–289<sup>C</sup> were reported to be unprotected. Second, structural models from scattering experiments suggest that conformational changes in R cause the release of one set of R/C contacts<sup>30</sup>, consistent with the Flipback conformation (Scheme 1). It has been shown that cAMP binding to CBD-B leads to increase H/D exchange at the B/C helix. It is likely that once binding to CBD-B, Flipback conformation is formed, leading to CBD-A association. Attempts to elucidate the heterotetrameric structure of PKA RIα with SAXS have proposed a Flipback-like conformation. Finally, the majority of R/C on RIα contacts result from interactions in CBD-A, consistent with Flipback.

Flipback dynamics are consistent with other molecular simulations and models.<sup>27, 34</sup> Guo *et al.* recently observed a flexible B/C helix when simulating apo-B form,<sup>9</sup> opposite to the starting point of our H form simulations. A backward-bending B/C helix is observed in these simulations, in conformation resembling Flipback. This suggests that F is a state accessible from both B and H forms.

An interesting role for Flipback emerges when we consider the termination phase of PKA regulation. Phosphodiesterase enzyme (PDE) hydrolyzes cAMP to 5′-cAMP, regulating concentration of the second messenger. Computational docking and HDXMS determined that for PDE to bind RIa subunit, the B/C helix requires a complete reorganization.<sup>35</sup> It is possible that Flipback is a binding partner of PDE, though further exanimation of this hypothesis is necessary.

Our simulations, coupled with experimental data make a case for a viable, and stable Flipback conformation of PKA RIa that may play important roles in the cAMP regulatory mechanism. Our work reveals a new structure of the WT PKA R subunit, which supports observations from ensemble-averaged solution structures and experiments. BD suggests a role for R<sup>Flipback</sup> conformation in mechanism of PKA activation. We hope our findings will lead to a re-examination PKA; especially on differences between the conformations of WT and R333K mutants, and the role of structural ensembles in ligand binding and ultimately, signal transduction.

# **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

# Acknowledgments

#### **Funding Sources**

This research was funded by a Fellowship from the Interfaces Graduate Training Program (NBIB T32 EB009380), and by the National Biomedical Computational Resource (NIH P41-GM103426) and NIH DP2 OD007237.

We especially acknowledge Dr. Alexandr Kornev for frequent and helpful discussions We acknowledge Drs. Jamie M. Schiffer, Susan S. Taylor, and Elizabeth Komives for their insights. Finally, we acknowledge Dr. Gary Huber and Dr. Lane W. Votapka for help and advice with BD simulations.

#### **ABBREVIATIONS**

PKA	Protein Kinase A	
cAMP	cyclic adenosine monophosphate	
CBD	cyclic-nucleotide binding domain	
В	cAMP-Bound	
Н	Holo	
F	Flipback	

#### References

- 1. Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL, Malinow R. Nat Neurosci. 2003; 6:136–143. [PubMed: 12536214]
- 2. Kamp TJ, Hell JW. Circ Res. 2000; 87:1095–1102. [PubMed: 11110765]
- 3. Johnson LN, Noble MEM, Owen DJ. Cell. 1996; 85:149–158. [PubMed: 8612268]
- 4. Chasiotis D. Acta Physiol Scand. 1985; 125:537-540. [PubMed: 3002131]

 Taylor SS, Zhang P, Steichen JM, Keshwani MM, Kornev AP. Bba-Proteins Proteom. 2013; 1834:1271–1278.

- Taylor SS, Ilouz R, Zhang P, Kornev AP. Nat Rev Mol Cell Bio. 2012; 13:646–658. [PubMed: 22992589]
- Su Y, Dostmann WRG, Herberg FW, Durick K, Xuong NH, Teneyck L, Taylor SS, Varughese KI. Science. 1995; 269:807–813. [PubMed: 7638597]
- 8. Kornev AP, Taylor SS, Ten Eyck LF. P Natl Acad Sci USA. 2008; 105:14377–14382.
- 9. Guo C, Zhou HX. P Natl Acad Sci USA. 2016; 113:E6776-E6785.
- 10. Kim C, Xuong NH, Taylor SS. Science. 2005; 307:690-696. [PubMed: 15692043]
- 11. Kim C, Cheng CY, Saldanha SA, Taylor SS. Cell. 2007; 130:1032–1043. [PubMed: 17889648]
- 12. Badireddy S, Gao YF, Ritchie M, Akamine P, Wu J, Kim CW, Taylor SS, Lin QS, Swaminathan K, Anand GS. Mol Cell Proteomics. 2011:10.
- 13. Boettcher AJ, Wu JA, Kim C, Yang J, Bruystens J, Cheung N, Pennypacker JK, Blumenthal DA, Kornev AP, Taylor SS. Structure. 2011; 19:265–276. [PubMed: 21300294]
- 14. Anand GS, Hotchko M, Brown SH, Ten Eyck LF, Komives EA, Taylor SS. Journal of molecular biology. 2007; 374:487–499. [PubMed: 17942118]
- 15. Anand GS, Hughes CA, Jones JM, Taylor SS, Komives EA. Journal of molecular biology. 2002; 323:377–386. [PubMed: 12381327]
- Anand GS, Law D, Mandell JG, Snead AN, Tsigelny I, Taylor SS, Ten Eyck LF, Komives EA. P Natl Acad Sci USA. 2003; 100:13264–13269.
- 17. Salomon-Ferrer R, Gotz AW, Poole D, Le Grand S, Walker RC. J Chem Theory Comput. 2013; 9:3878–3888. [PubMed: 26592383]
- 18. Pecora de Barros E, Malmstrom RD, Nourbakhsh K, Del Rio JC, Kornev AP, Taylor SS, Amaro RE. Biochemistry-Us. 2017; 56:1536–1545.
- Malmstrom RD, Kornev AP, Taylor SS, Amaro RE. Nat Commun. 2015; 6:7588. [PubMed: 26145448]
- Cheng, CY. Chemistry. UC San Diego: 2009. Dissecting the allosteric regulation of PKA-I alpha activation.
- 21. Sjoberg TJ, Kornev AP, Taylor SS. Protein Sci. 2010; 19:1213–1221. [PubMed: 20512974]
- 22. Northrup SH, Allison SA, Mccammon JA. J Chem Phys. 1984; 80:1517–1526.
- 23. Ermak DL, Mccammon JA. J Chem Phys. 1978; 69:1352-1360.
- 24. Votapka LW, Amaro RE. PLoS computational biology. 2015:11.
- 25. Huber GA, McCammon JA. Comput Phys Commun. 2010; 181:1896–1905. [PubMed: 21132109]
- 26. Herberg FW, Taylor SS, Dostmann WRG. Biochemistry-Us. 1996; 35:2934-2942.
- 27. Boras BW, Kornev A, Taylor SS, McCulloch AD. The Journal of biological chemistry. 2014; 289:30040–30051. [PubMed: 25202018]
- 28. Vigil D, Blumenthal DK, Heller WT, Brown S, Canaves JM, Taylor SS, Trewhella J. Journal of molecular biology. 2004; 337:1183–1194. [PubMed: 15046986]
- 29. Cheng CY, Yang J, Taylor SS, Blumenthal DK. Journal of Biological Chemistry. 2009; 284:35916–35925. [PubMed: 19837668]
- 30. Heller WT, Vigil D, Brown S, Blumenthal DK, Taylor SS, Trewhella J. Journal of Biological Chemistry. 2004; 279:19084–19090. [PubMed: 14985329]
- 31. Moorthy BS, Badireddy S, Anand GS. Int J Mass Spectrom. 2011; 302:157-166.
- 32. Hamuro Y, Anand GS, Kim JS, Juliano C, Stranz DD, Taylor SS, Woods VL. Journal of molecular biology. 2004; 340:1185–1196. [PubMed: 15236976]
- 33. Huang LJ, Taylor SS. The Journal of biological chemistry. 1998; 273:26739–26746. [PubMed: 9756917]
- 34. Boras BW, Hirakis SP, Votapka LW, Malmstrom RD, Amaro RE, McCulloch AD. Front Physiol. 2015; 6:250. [PubMed: 26441670]
- 35. Krishnamurthy S, Moorthy BS, Xiang LX, Shan LX, Bharatham K, Tulsian NK, Mihalek I, Anand GS. Biophys J. 2014; 107:1426–1440. [PubMed: 25229150]





FIGURE 1. Comparison of known RIa conformations

(A)  $R^{Bound}$ :cAMP<sub>2</sub>; The Bound or B conformation, RIa (purple ribbon) with two molecules of cAMP (licorice). (B)  $R^{Holo}$ :C; The Holo or H conformation, RIa (purple ribbon) in complex with the C subunit (white ribbon). (C)  $R^{Flipback}$ :C; The Flipback conformation or F conformation, an MD-derived metastable state, aligned with Ca subunit (white ribbon). B/C helices are shown in gold ribbon. In light purple, the N3A motifs of A and B (N3A<sup>A</sup> and N3A<sup>B</sup>) are shown. The C subunit is shown with ATP (licorice). Blue surface representation highlights the H/D exchanging regions of the C subunit measured by HDXMS.



SCHEME 1. Activation mechanism of PKA RIa with different R conformations and relative association rates

Table 1

Comparison of cAMP association rates to cyclic nucleotide binding domains of PKA complexes

cAMP binding Domain (CBD)	PKA Conformation	$\mathbf{k}_{\mathrm{association}} \ (\mathbf{M}^{-1},  \mathbf{s}^{-1})$
A	$R_2C_2{}^{Holo}$	$3.07 \times 10^5$
В	$R_2C_2{}^{Holo}$	$2.57 \times 10^7$
A	$ m R_2C_2^{Flipback}$	$4.29 \times 10^6$
В	$ m R_2C_2^{Flipback}$	4.16 x 10 <sup>6</sup>
A	RC <sup>Holo</sup>	2.50 x 10 <sup>4</sup>
В	RCHolo	$2.72 \times 10^4$
A	RCFlipback	1.38 x 10 <sup>8</sup>
В	<b>RC</b> Flipback	1.98 x 10 <sup>6</sup>